Description

Jasper Therapeutics, Inc. is a biotechnology company in the clinical development phase, dedicated to creating and advancing therapeutic agents for both hematopoietic stem cell transplantation and gene therapies. Their strategic focus encompasses the development and eventual commercialization of treatments for a variety of conditions. These include chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and the formulation of innovative preparatory treatments (conditioning regimens) for stem cell transplantation and ex-vivo gene therapy – a method where cells are genetically modified outside the body before being transplanted back into a patient. The company's lead investigational product is briquilimab, a novel therapeutic antibody undergoing clinical trials. Briquilimab functions by clearing hematopoietic stem cells from a patient's bone marrow before they receive an allogeneic stem cell or stem cell gene therapy. In addition, Jasper Therapeutics is engineering specialized hematopoietic stem cell product candidates designed to overcome critical limitations often encountered with allogeneic and autologous gene-edited stem cell grafts. The company's corporate headquarters are located in Redwood City, California.